INVIVYD INC. - COMMON

Invivyd Appoints Fred Driscoll as Interim Chief Financial Officer and Announces Resource Reallocation to Maximize Integrated Discovery Platform

13 10 2022 16:01:00 提供 Nasdaq GlobeNewswire

Invivyd to Present Multiple Posters Highlighting Clinical Data from Adintrevimab During ID Week 2022

12 10 2022 16:01:00 提供 Nasdaq GlobeNewswire

Invivyd Announces Multiple Next Generation COVID-19 Antibody Candidates and Selects Combination for Clinical Advancement Based on Positive in vitro Data Against Omicron Variants

12 9 2022 07:15:00 提供 Nasdaq GlobeNewswire

Adagio Therapeutics Announces Corporate Name Change to Invivyd

12 9 2022 07:00:01 提供 Nasdaq GlobeNewswire

Adagio Therapeutics to Participate in Upcoming Investor Conferences

06 9 2022 16:01:00 提供 Nasdaq GlobeNewswire

Adagio Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights

15 8 2022 06:30:00 提供 Nasdaq GlobeNewswire

Adagio Announces David Hering Named Permanent Chief Executive Officer and Director

05 7 2022 07:25:58 提供 Nasdaq GlobeNewswire

Adagio Announces Results of Annual Meeting of Stockholders and Evolution of the Board of Directors

01 7 2022 06:30:00 提供 Nasdaq GlobeNewswire

Adagio Therapeutics Reports First Quarter 2022 Financial Results

13 5 2022 06:30:00 提供 Nasdaq GlobeNewswire

Adagio Therapeutics Provides Update on Timing of Adintrevimab EUA Request

14 4 2022 07:45:00 提供 Nasdaq GlobeNewswire

Adagio Therapeutics Announces ADG20 (adintrevimab) is the First Monoclonal Antibody to Meet Primary Endpoints with Statistical Significance Across Pre- and Post-exposure Prophylaxis and Treatment for COVID-19 and Plans to Seek U.S. Emergency Use Authorization

30 3 2022 06:30:00 提供 Nasdaq GlobeNewswire

Adagio Therapeutics, Inc. Announces 2022 Annual Meeting of Stockholders

18 3 2022 18:33:15 提供 Nasdaq GlobeNewswire

Adagio Therapeutics Announces David Hering Appointed Interim Chief Executive Officer

23 2 2022 16:30:00 提供 Nasdaq GlobeNewswire

Adagio Therapeutics Announces ADG20 Development Plans and Pipeline Updates

22 2 2022 07:30:00 提供 Nasdaq GlobeNewswire

Adagio Therapeutics Announces CEO Succession Plan

18 2 2022 19:33:28 提供 Nasdaq GlobeNewswire

Adagio Therapeutics Summarizes ADG20 Neutralizing Activity Against SARS-CoV-2 Variants and Outlines Initiatives to Address Omicron

12 1 2022 16:56:55 提供 Nasdaq GlobeNewswire

Adagio Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

06 1 2022 06:30:00 提供 Nasdaq GlobeNewswire

Adagio Therapeutics Reports Reduction in In Vitro Neutralizing Activity of ADG20 Against Omicron SARS-CoV-2 Variant

14 12 2021 07:00:00 提供 Nasdaq GlobeNewswire

Adagio Therapeutics Reports That None of the Mutations Present in SARS-CoV-2 Variant, Omicron, Are Associated with Escape from ADG20 Neutralization In Vitro

29 11 2021 06:30:00 提供 Nasdaq GlobeNewswire

Adagio Therapeutics Announces Expansion of Management Team and Board of Directors to Support Rapid Advancement and Commercial Readiness of ADG20 for COVID-19

22 11 2021 06:30:00 提供 Nasdaq GlobeNewswire